Clinical Design and Current Status

The INTACT·S1806 trial, led by the U.S. National Cancer Institute (NCI), is a randomized phase 3 study involving 475 patients with locally advanced muscle-invasive bladder cancer (MIBC). It compares definitive chemoradiation therapy (CRT) alone with a combination of Tecentriq (atezolizumab). The trial has completed enrollment and is currently in the follow-up phase. The primary endpoint is bladder-intact progression-free survival (BI-EFS), with overall survival (OS), pathological response at 18 weeks, and quality of life also being evaluated. ClinicalTrials.gov indicates a projected primary completion date of June 2027, meaning efficacy conclusions will not be available until the results are released.

Drug and Combination Strategy

Tecentriq, from Roche's Genentech, is an approved immune checkpoint inhibitor that blocks PD-L1 on tumor and immune cells. The experimental arm combines radiation with gemcitabine, cisplatin, or 5-FU/mitomycin-C, with atezolizumab administered intravenously every three weeks for a total of nine cycles. This approach combines radiation-induced tumor antigen release with PD-L1 blockade, aiming to simultaneously enhance local control and systemic immune responses. Success could provide evidence for adding immunotherapy to trimodal therapy (TMT) to avoid bladder removal.

Competitive Landscape and Standard of Care

The current standard of care for curative intent involves cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy. In selected patients, chemoradiation therapy concurrent with maximum cystectomy is an alternative bladder-sparing approach. The main competitor is Imfinzi (durvalumab), an anti-PD-L1 antibody from AstraZeneca (AZN), which the FDA approved on March 28, 2025, for use in combination with gemcitabine and cisplatin as adjuvant therapy after surgery. Keytruda (pembrolizumab), a PD-1 inhibitor from Merck (MRK), and Padcev (enfortumab vedotin), a Nectin-4 ADC from Astellas (4503.T), both had their indications for neoadjuvant and adjuvant treatment of MIBC expanded to include all surgical candidates on July 10, 2026. However, as both competing strategies rely on cystectomy, the key differentiator for S1806 is long-term bladder preservation.

Regulatory and Market Implications

The FDA approved Tecentriq as adjuvant therapy for MIBC with circulating tumor DNA (ctDNA) minimal residual disease (MRD) after cystectomy on May 15, 2026. This supports the biological activity of atezolizumab in MIBC, but the combination with chemoradiation and the bladder-sparing indication in S1806 require separate phase 3 validation. The global bladder cancer therapeutics market is estimated to have grown from USD 5.56 billion in 2024 to USD 5.97 billion in 2025, making the expansion of immunotherapy to earlier stages a key commercial driver. Positive BI-EFS results would open up a differentiated market for Roche, targeting patients who can avoid surgery, but this will depend on demonstrating acceptable safety, quality of life, and rates of subsequent cystectomy.